You are here

Article info

Article menu

Download PDFPDF

Vasculitis
Short report
Daratumumab for the treatment of refractory ANCA-associated vasculitis

Authors

  • Lennard Ostendorf Department of Nephrology and Medical Intensive Care Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyDeutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Marie Burns Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Dimitrios Laurin Wagner BIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, GermanyBerlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, GermanyInstitute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyInstitute of Medical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Philipp Enghard Department of Nephrology and Medical Intensive Care Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyDeutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Kerstin Amann Department of Nephropathology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Henrik Mei Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Kai-Uwe Eckardt Department of Nephrology and Medical Intensive Care Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Evelyn Seelow Department of Nephrology and Medical Intensive Care Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Adrian Schreiber Department of Nephrology and Medical Intensive Care Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Lennard Ostendorf; lennard.ostendorf{at}charite.de
View Full Text

Citation

Ostendorf L, Burns M, Wagner DL, et al
Daratumumab for the treatment of refractory ANCA-associated vasculitis
RMD Open 2023;9:e002742. doi: 10.1136/rmdopen-2022-002742

Publication history

  • Received September 19, 2022
  • Accepted December 23, 2022
  • First published January 10, 2023.
Online issue publication 
February 14, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.